The therapeutic substance is generally applied across domains where additional symptomatic support is needed, primarily for its regenerative and immunotropic properties.

The medication is commonly used across conditions presenting with acute episodes where the immune system is under strain, such as Acute Respiratory Viral Infections (ARVI), or in complex cases involving chronic tissue defects like trophic ulcers and non-healing wounds. It is also considered relevant in contexts involving heightened systemic burden or vulnerability, such as reducing the level of intoxication in severe conditions or supporting patients during episodes of physiological strain. These applications support general well-being during symptomatic phases by providing supportive relief when symptoms interfere with routine activities.

“It is commonly used to help with supporting patients during episodes of heightened discomfort during challenging phases.”

---

QuickFact

Quick Fact: Supportive Relief Domains
Symptom Category: Relief is targeted at symptom clusters related to systemic imbalance (e.g., intoxication), infectious processes (e.g., ARVI), and impaired tissue repair (e.g., chronic wounds).

---

Categories of Use and Supportive Relief

The substance is relevant for easing symptoms tied to conditions involving infectious processes (like acute respiratory viral infections and specific urogenital tract infections), significant systemic discomfort (like severe systemic inflammatory responses), and chronic tissue pathologies (such as trophic ulcers and non-healing wounds).

The eligibility profile for Derinat (Sodium Deoxyribonucleate) is established by official regulatory documentation and clearly defines populations for whom the medicine is contraindicated or requires conditional use.

Absolute Contraindications

The medicine must not be administered to individuals with a known individual intolerance or hypersensitivity to the active substance or any excipients. Use is strictly contraindicated for women who are pregnant. Furthermore, the systemic 1.5% solution is prohibited during the lactation period (breastfeeding).

Age-Related Eligibility

Derinat is approved for use across all age groups, extending from infants to adults. While eligibility is comprehensive, pediatric use of the systemic 1.5% solution requires adherence to specific dose calculations based on the child's age or weight.

Condition-Based Caution

Patients with Diabetes Mellitus are permitted to use Derinat, but use is conditional and requires caution. Official labeling specifies that the drug exhibits a moderate hypoglycemic action, making blood glucose monitoring a necessary requirement throughout the entire course of therapy. No formal restrictions related to severe hepatic or renal impairment are documented in the prescribing information.

Interactions with other medicines and products

The official regulatory profile for Derinat (Sodium Deoxyribonucleate) is defined by its role in complex therapy, primarily demonstrating pharmacodynamic interactions rather than pharmacokinetic effects involving CYP enzymes or drug transporters.

Documented Interaction Patterns

The drug is officially noted to influence the efficacy of several co-administered medicinal product categories, which may necessitate adjustments to their required dosages.

Interaction Type	Interacting Product Category	Official Regulatory Description
Potentiation/Dose Reduction	Antibiotics and Antiviral Drugs	Increases treatment efficiency and may allow for a significant decrease in the required dosage of these agents.
Therapeutic Potentiation	Cytostatics, Antitumor Antibiotics	Officially stated to increase the efficiency of these specific antineoplastic agents.
Effect Mitigation	Basic Drugs for Rheumatoid Arthritis	Noted to reduce the iatrogenic side-effects of these co-administered drugs.
Hypoglycemic Action	Antidiabetic drugs (in diabetic patients)	A moderate hypoglycemic action is noted, requiring consideration relative to the patient's existing antidiabetic regimen.

Contraindications and Administration Rules

No medicinal products or substances are formally listed as contraindicated for co-administration in the official documentation. Furthermore, the label does not include any mandatory timing or separation requirements for concurrent administration. Interactions with food, alcohol, or herbal products are not documented in the regulatory profile.

How Derinat Works: Mechanism of Action

Derinat, containing Sodium Deoxyribonucleate, acts as an immunomodulator primarily by engaging Pattern Recognition Receptors (PRRs), such as TLR9, found on immune cells like macrophages and dendritic cells. This interaction initiates intracellular signaling cascades that modulate the functional activity of both the innate and adaptive immune systems, influencing the systemic coordination of defensive processes.

Concurrently, the active ingredient provides deoxyribonucleotide fragments readily utilized by cells in the salvage pathway of nucleotide metabolism. This supplies precursors for the biosynthesis of nucleic acids, accelerating DNA repair and stimulating the proliferation and differentiation of cells. This action results in increased turnover rates in rapidly dividing tissues, including the skin and mucous membranes.

Furthermore, the drug modulates inflammatory signaling cascades by influencing the release kinetics of certain cytokines. It also functions as a scavenger of Reactive Oxygen Species (ROS), directly neutralizing harmful free radicals. This combined action supports the clearance of ROS and influences the kinetics of inflammatory pathway deactivation.

How to Use Derinat: Administration Guidelines

Administration of Derinat (Sodium Deoxyribonucleate) is governed by two distinct protocols based on the formulation strength and intended route. The medication is available as a 1.5% solution for systemic parenteral administration and a 0.25% solution for local and outward use.

---

Administration Routes and Dosing

The most common systemic approach is Intramuscular (IM) injection, although the subcutaneous route is also indicated. For systemic treatment, the single adult unit dose is standardized at 5 ml (75 mg). This systemic use is strictly organized into predefined treatment courses, with the total number of injections varying (e.g., 3 to 15 injections) depending on the condition being addressed.

---

Frequency and Procedural Rules

IM injections follow a variable intermittent schedule, with the interval between doses changing between 24, 48, or 72 hours over the course of the treatment cycle. To ensure proper administration, the intramuscular injection must be delivered slowly, taking approximately 1 to 2 minutes. The drug is supplied as a sterile, ready-to-use solution that requires no preparation or dilution prior to administration.

---

Pediatric Dosing Rules

Specific dosage guidelines exist for pediatric populations. For children under two years old, the single IM dose is 0.5 ml (7.5 mg). For children aged two to ten years, the dose is calculated based on age, using a ratio of 0.5 ml for every year of life. Children ten years and older receive the standard adult unit dose of 5 ml.

Research Evidence / Overview of Studies for Derinat

The research evidence for the active ingredient, Sodium Deoxyribonucleate, was studied in different clinical situations. This overview describes the types of studies that exist and what they examined, without providing any clinical guidance or recommendations. The information presented is derived from regulatory-cited sources and peer-reviewed scientific literature.

---

Research Evidence for Acute Respiratory Infections (ARIs)

Research exploring the agent's application in acute respiratory infections (ARIs), such as the common cold and flu-like illnesses (ARVI), is based on clinical trials. Randomized Controlled Trials (RCTs) and various observational studies were used in research exploring how symptoms change over time in both adults and children who were experiencing conditions associated with acute or disruptive episodes. Studies monitored outcomes related to physical discomfort. Research highlights changes measured during the study period related to the resolution of episodic or acute changes in symptoms in the observed populations. The follow-up durations were limited in many of these trials, and the evidence quality varies across studies, which contributes to the uncertainty.

Research Evidence for Chronic Tissue Repair and Wounds

The research exploring the agent's application in conditions marked by functional limitations like trophic ulcers and non-healing wounds was observed in pre-clinical settings, including the use of pre-clinical and experimental models. Localized, small-scale clinical application studies research examined the agent in contexts where outcomes reflecting daily functioning or activity level related to the wound was observed. Certainty remains low for this application because the clinical evidence available is often limited to small-scale reports. There is a lack of large-scale, high-quality comparative evidence showing how its use may perform alongside the established standard of care for chronic wounds.

Research Gaps and What is Still Uncertain About Derinat

Studies help show what has been observed so far, and the evidence base highlights what is known, and what is still uncertain across all studied conditions. Evidence is limited in determining the long-term impact of the agent, as most studies explored short-term symptom changes. Sample sizes were modest in many of the core clinical trials, and comparative evidence is lacking for many applications. Currently, there is limited information for long-term outcomes across all researched applications.

Common questions about Derinat (FAQ)

Q: Can Derinat be used while breastfeeding?

A: Official regulatory information lists the lactation (breastfeeding) period as a contraindication for the systemic 1.5% solution. However, the use of the drug in lactating women is described as conditional and only on prescription, requiring an assessment of expected benefit versus potential risk.

Q: How quickly does Derinat typically start working?

A: Official research documents indicate that the effect of the drug is generally measured in the context of a short-term course of treatment. For example, research examining respiratory infections monitored changes in symptoms over an average period of up to 30 days.

Q: How long is the usual treatment period with Derinat?

A: According to the official product information, the total duration of a treatment course is not fixed and varies based on the specific condition being addressed. This typically involves a set number of injections, often ranging from 3 to 15, delivered on an intermittent schedule.

Q: What kind of studies (e.g., clinical trials) have been conducted on Derinat?

A: Official research documents indicate that the evidence base for the active ingredient is drawn from various sources. These include formal studies such as Randomized Controlled Trials (RCTs) and observational studies, as well as reports from pre-clinical settings and small-scale clinical applications.

Q: Does Derinat require any special preparation before use?

A: Official instructions confirm that the solution is supplied as a sterile, ready-to-use product. The documentation specifically states that the drug requires no preparation or dilution prior to administration.

Q: Why is Derinat sometimes described as an immunomodulator?

A: Derinat is classified as an immunomodulator because it acts by influencing the body's defensive response. Regulatory documents describe its mechanism as engaging Pattern Recognition Receptors on immune cells, which helps modulate the functional activity of both the innate and adaptive immune systems.

Q: Are there any food or drink restrictions while using Derinat?

A: Official regulatory documents indicate that interactions between Derinat and food, alcohol, or herbal products are not documented in the drug's safety profile.

Q: Where is Derinat primarily manufactured?

A: According to the product holder's official company information, the drug is primarily manufactured in Moscow, Russia.

Q: Is there research evidence on Derinat for viral infections?

A: Research has explored the agent’s use in conditions associated with Acute Respiratory Infections (ARIs), such as flu-like illnesses. These are a category of illnesses that are often associated with viral causes.

Q: Is Derinat safe for long-term use?

A: Research exploring the agent's effects primarily focuses on short-term symptom changes. Current regulatory documents state that there is limited information available regarding the long-term impact of the drug.

Q: Are there specific warnings for people with kidney or liver problems?

A: Official prescribing information states that no formal restrictions or specific warnings related to severe hepatic (liver) or renal (kidney) impairment are documented for the product.

Q: What does the research say about Derinat's effect on wound healing?

A: Research has explored the agent’s application in conditions involving chronic tissue damage, such as non-healing wounds. The agent is described in official documents as stimulating biological processes responsible for cellular repair and tissue healing.

Q: Is it normal to see an improvement quickly or does it take time?

A: Official research documents indicate that the effect is generally measured in the context of a short-term course of treatment. For example, research examining respiratory infections monitored changes in symptoms over an average period of up to 30 days.

Q: Does Derinat affect blood cell formation?

A: Official product information recognizes Derinat for its auxiliary role as a hemopoietic agent. This is due to its stated capacity to influence the regulation of blood cell formation.

Q: What is the source of the active ingredient (Sodium Deoxyribonucleate)?

A: The active ingredient, Sodium Deoxyribonucleate, is described as being of natural origin. It is isolated through a high-level purification process from the soft roes of sturgeon fish.

How to Store and Dispose of Derinat

Official regulatory documentation specifies precise conditions for the storage of Derinat solution to maintain its stability.

Storage Requirements

The intramuscular solution must be stored within a mandatory temperature range of +4 C to +20 C. The product must be protected from freezing, and storage should occur in a shadowed place to prevent light exposure. The medicine must be saved away from children, ensuring it is kept out of their sight and reach.

Stability and Disposal

The product has a specified validity period of 5 years when stored correctly in its unopened, original package. The medicine must not be used after this expiration date. For disposal, any unused or expired Derinat product must be handled in accordance with local regulations for pharmaceutical waste, as specific household disposal instructions are not provided in the official labeling.